Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women

Journal of the National Cancer Institute

Volumn 90, Issue 17, 1998, Pages 1292-1299

  Hankinson, Susan E ^a,d   Willett, Walter C ^a   Manson, JoAnn E ^b   Colditz, Graham A ^a   Hunter, David J ^a   Spiegelman, Donna ^b   Barbieri, Robert L ^c   Speizer, Frank E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; ESTRADIOL; PRASTERONE; SEX HORMONE; TESTOSTERONE;

ADULT; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; POPULATION RESEARCH; POSTMENOPAUSE; TESTOSTERONE BLOOD LEVEL;

EID: 0032475436     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.17.1292     Document Type: Article

References (69)

1. Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev 1993; 15:48-65.
2. Huang Z, Hankinson SE, Colditz GA, Stampfer MJ, Hunter DJ, Manson JE, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA 1997;278:1407-11.
3. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350: 1047-59.
4. Dao TL. The role of ovarian steroid hormones in mammary carcinogenesis. In: Pike MC, Siiteri PK, Welsch CW, editors. Hormones and breast cancer. Banbury Report No. 8. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory: 1981. p. 281-95.
5. Lippman M, Bolan G, Huff K. The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 1976;36:4610-8.
6. James VH, McNeill JM, Lai LC, Newton CJ, Ghilchik MW, Reed MJ. Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies. Steroids 1987;50:269-79.
7. Thijssen JH, Blankenstein MA, Donker GH, Daroszewski J. Endogenous steroid hormones and local aromatase activity in the breast. J Steroid Biochem Mol Biol 1991;39: 799-804.
8. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995;87:190-7.
9. Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW. A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 1994;18:79-85.
10. Dorgan JF, Longcope C, Stephenson HE Jr, Falk RT, Miller R, Franz C, et al. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prev 1996;5:533-9.
11. Berrino F, Muti P, Micheli A, Bolelli G, Krogh V, Sciajno R, et al. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996;88:291-6.
12. Thomas HV, Key TJ, Allen DS, Moor JW, Dowsett M, Fentiman IS, et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in postmenopausal women on the island of Guernsey. Br J Cancer 1997;76:401-5.
13. Garland CF, Friedlander NJ, Barrett-Connor E, Khaw KT. Sex hormones and postmenopausal breast cancer: a prospective study in an adult community. Am J Epidemiol 1992;135: 1220-30.
14. Thomas HV, Reeves GK, Key TJ. Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control 1997;8:922-8.
15. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE. Reproducihility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomarkers Prev 1995;4: 649-54.
16. Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA, Stampfer MJ, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 1995;87:1297-302.
17. Hankinson SE, London SJ, Chute CG, Barbieri RL, Jones L, Kaplan LA, et al. Effect of transport conditions on the stability of biochemical markers in blood. Clin Chem 1989;35:2313-6.
18. Abraham GE, Tulchinsky D, Korenman SG. Chromatographic purification of estradiol-17β for use in radio-ligand assay. Biochem Med 1970;3:365-8.
19. Mikhail G, Chung HW. Radioimmunoassay of plasma estrogens. Use of polymerized antibodies. In: Peron FG, Caldwell BV, editors. Immunologic methods in steroid determination. New York: Appleton-Century-Crofts; 1970. p. 113.
20. Kinouchi T, Pages L, Horton R. A specific radioimmunoassay for testosterone in peripheral plasma. J Lab Clin Med 1973;82:309-16.
21. McNatty KP, Smith DM, Makris A, Osathanondh R, Ryan KJ. The microenvironment of the human antral follicle: interrelationships among the steroid levels in antral fluid, the population of granulosa cells, and the status of the oocyte in vivo and in vitro. J Clin Endocrinol Metab 1979;49:851-60.
22. Buster JE, Abraham GE. Radioimmunoassay of plasma dehydroepiandrosterone sulfate. Anal Lett 1972;5:543.
23. Moll GW Jr. Rosenfield RL, Helke JH. Estradiol-testosterone binding interactions and free plasma estradiol under physiological conditions. J Clin Endocrinol Metab 1981;52: 868-74.
24. Vermeulen A, Stoica T, Verdonck L. The apparent free testosterone concentration. an index of androgenicity. J Clin Endocrinol Metab 1971;33:759-67.
25. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperature. J Steroid Biohem 1982;16:801-10.
26. Stumpf PG, Nakamura RM, Mishell DR Jr. Changes in physiologically free circulating estradiol and testosterone during exposure to levonorgestrel. J Clin Endocrinol Metab 1981; 52:138-43.
27. Franz C, Watson D, Longcope C. Estrone sulfate and dehydroepiandrosterone sulfate concentrations in normal subjects and men with cirrhosis. Steroids 1979;34:563-73.
28. Liang IK, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
29. Rothman KJ. Modern epidemiology. 1st ed. Boston: Little, Brown & Co.; 1986. p. 237-83.
30. Rosner B. Fundamentals of biostatistics. 4th ed. Belmont (CA): Wadsworth Publishing Co.: 1993.
31. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley; 1989.
32. Carroll RJ, Ruppert D, Stefanski LA. Measurement error in nonlinear models. London: Chapman & Hall: 1995.
33. Prentice RL. Covariate measurement errors and parameter estimation in a failure time regression model. Biometrika 1982;69:331-42.
34. Wang CY, Hsu L, Feng ZD, Prentice RL. Regression calibration in failure time regression. Biometrics 1997;53:131-45.
35. Spiegelman D, McDermott A, Rosner B. Regression calibration methods for correcting measurement-error bias in nutritional epidemiology. Am J Clin Nutr 1997;65(4 Suppl): 1179S-1186S.
36. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989;8: 551-61.
37. Hankinson SE, Manson JE, London SJ, Willett WC, Speizer FE. Laboratory reproducibility of endogenous hormone levels in postmenopausal women. Cancer Epidemiol Biomarkers Prev 1993;3:51-6.
38. Potischman N, Falk RT Laiming VA, Siiteri PK, Hoover RN. Reproducibility of laboratory assays for steroid hormones and sex hormone-binding globulin. Cancer Res 1994;54:5363-7.
39. Siiteri PK, Hammond GL, Nisker JA. Increased availability of serum estrogens in breast cancer: a new hypothesis. Banbury Rep 1981;8:87-106.
40. Moore JW, Clark GM, Hoare SA, Millis RR, Hayward JL, Quinlan MK, et al. Binding of oestradiol to blood proteins and aetiology of breast cancer. Int J Cancer 1986;38:625-30.
41. Siiteri PK, Simberg N, Murai J. Estrogens and breast cancer. Ann N Y Acad Sci 1986;464: 100-5.
42. Reed MJ, Cheng RW, Noel CT, Dudley HA, James VH. Plasma levels of estrone. estrone sulfate. and estradiol and the percentage of unbound estradiol in postmenopausal women with and without breast disease. Cancer Res 1983;43:3940-3.
43. Ernster VL, Wrensch MR, Petrakis NL, King EB, Miike R, Murai J, et al. Benign and malignant breast disease: initial study results of serum and breast fluid analyses of endogenous estrogens. J Natl Cancer Inst 1987;79:949-60.
44. Longcope C, Franz C, Morello C, Baker R, Johnston CC Jr. Steroid and gonadotropin levels in women during the peri-menopausal years. Maturitas 1986;8:189-96.
45. Roberts KD, Rochefort JG, Bleau G, Chapdelaine A. Plasma estrone sulfate levels in postmenopausal women. Steroids 1980;35:179-87.
46. Zeleniuch-Jacquotte A, Bruning PF, Bonfrer JM, Koenig KL, Shore RE, Kim MY, et al. Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. Am J Epidemiol 1997;145:1030-8.
47. Secreto G, Toniolo P, Berrino F, Recchione C, Cavalleri A, Pisani P, et al. Serum and urinary androgens and risk of breast cancer in postmenopausal women. Cancer Res 1991;51: 2572-6.
48. Adami HO, Johansson ED, Vegelius J, Victor A. Serum concentrations of estrone, androstenedione, testosterone and sex-hormone-binding globulin in postmenopausal women with breast cancer and in age-matched controls. Ups J Med Sci 1979;84:259-74.
49. Secreto G, Recchione C, Cavalleri A, Miraglia M, Dati V. Circulating levels of testosteroe, 17β-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients. Br J Cancer 1983;47:269-75.
50. Wysowski DK, Comstock GW, Helsing KJ, Lau HL. Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol 1987;125:791-9.
51. Garland CF, Friedlander NJ, Barrett-Connor E, Khaw KT. Sex hormones and postmenopausal breast cancer: a prospective study in an adult community. Am J Epidemiol 1992;135: 1220-30.
52. Ebeling P, Koivisto VA. Physiological importance of dehydroepiandrosterone. Lancet 1994; 343:1479-81.
53. Gordon GB, Shantz LM, Talalay P. Modulation of growth, differentiation and carcinogenesis by dehydroepiandrosterone. Adv Enzyme Regul 1987;26:355-82.
54. Seymour-Munn K, Adams J. Estrogenic effects of 5-androstene-3β, 17β-diol at physiological concentrations and its possible implication in the etiology of breast cancer. Endocrinology 1983;112:486-91.
55. Barrett-Connor E, Friedlander NJ, Khaw KT. Dehydroepiandrosterone sulfate and breast cancer risk. Cancer Res 1990;50:6571-4.
56. Gordon GB, Bush TL, Helzlsouer KJ, Miller SR, Comstock GW. Relationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing postmenopausal breast cancer. Cancer Res 1990;50:3859-62.
57. Longcope C. Metabolism of dehydroepiandrosterone. Ann N Y Acad Sci 1995;774: 143-8.
58. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age [published erratum appears in J Clin Endocrinol Metab 1995;80:2799]. J Clin Endocrinol Metab 1994;78:1360-7.
59. Bruning PF, Van Doorn J, Bonfrer JM, Van Noord PA, Korse CM, Linders TC, et al. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable premenopausal breast cancer [published erratum appears in Int J Cancer 1995;63:762]. Int J Cancer 1995;62: 266-70.
60. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351:1393-6.
61. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
62. Thijssen JH, Blankenstein MA. Endogenous oestrogens and androgens in normal and malignant endometrial and mammary tissues. Eur J Cancer Clin Oncol 1989;25:1953-9.
63. Vermeulen A, Deslypere JP, Paridaens R, Leclercq G, Roy F, Heuson JC. Aromatase. 17β-hydroxysteriod dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol 1986;22:515-25.
64. van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 1985;45:2900-6.
65. Perel E, Blackstein ME, Killinger DW. Aromatase in human breast carcinoma. Cancer Res 1982;42(8 Suppl):3369s-3372s.
66. Iqbal MJ, Valyani SH, Roberts JV. Mechanisms of sex-steroid accumulation in the aetiology of human breast carcinoma: the role of intracellular sex hormone binding globulin. Anticancer Res 1988;8:479-81.
67. Thijssen JH, Blankenstein MA, Miller WR, Milewicz A. Estrogens in tissues: uptake from the peripheral circulation or local production. Steroids 1987;50:297-306.
68. Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 1998;90: 814-23.
69. Cauley JA, Gutai JP, Kuller LH, LeDonne D, Sandler RB, Sashin D, et al. Endogenous estrogen levels and calcium intakes in postmenopausal women. Relationships with cortical bone measures. JAMA 1988;260:3150-5.